Nevada’s Vetoed Insulin Cost Transparency Bill Returns, as California Advances Several Pricing Measures Post author:Sam Post published:June 5, 2017 Post category:Drug Industry Daily Lawmakers in Nevada and California continue to target drugmakers in health care proposals. Source: Drug Industry Daily You Might Also Like FDA Funding Bill Advances in the House June 28, 2017 PBMs May Be Complicit in Schemes to Curb Price Competition, Gottlieb Says April 20, 2018 FDA Warns Mylan Facility Over Quality and Data Issues April 11, 2017